PLYMOUTH MEETING, PA, June 17, 2019 — Harmony Biosciences, LLC (Harmony) today announced the launch of the first Patients at the Heart Grant, a competitive grant opportunity to fund innovative patient-centric programs for the narcolepsy community. As part of Harmony’s overall commitment to supporting the comprehensive needs of people living with narcolepsy, Harmony has committed an initial $50,000 to this program.
“Keeping patients at the heart of everything we do is our main focus,” said Cate McCanless, Harmony’s Vice President, External Affairs. “We recognize there is an unmet need for support within the narcolepsy community and are hopeful we receive innovative ideas from organizations that allow us to support people living with narcolepsy and their families.”
Charitable grant applications should focus on one or more of the following categories:
Applications from eligible organizations are being accepted through Monday, August 19, 2019. Announcement of grant recipients will take place on World Narcolepsy Day, Sunday, September 22, 2019. For more information, please see the program overview document and application, or contact patientsattheheart@harmonybiosciences.com.
Harmony Biosciences, LLC
Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, starting with patients living with narcolepsy. Harmony is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. For more information on Harmony Biosciences, visit www.harmonybiosciences.com.
Harmony Biosciences, LLC Media Contact:
Nancy Leone
215-891-6046
nleone@harmonybiosciences.com